Loading clinical trials...
Loading clinical trials...
Phase I: will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer. Phase II...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, and more
NCT05660083 · HER2-negative Breast Cancer, Metastatic Breast Cancer, and more
NCT07354022 · Locally Advanced or Metastatic Breast Cancer
Wilshire Oncology Medical Group La Verne
*see Various Departments*, California
Compassionate Cancer Care Medical Group Dept.ofCCCMG
Fountain Valley, California
Loma Linda University Dept.ofLomaLindaCancerCent(3)
Loma Linda, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions